 <h1>Akynzeo Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>netupitant / palonosetron</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about netupitant / palonosetron. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Akynzeo.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to netupitant/palonosetron: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, netupitant / palonosetron may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking netupitant / palonosetron:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>confusion</li>
<li>dizziness</li>
<li>fever</li>
<li>hearing or seeing things that are not there</li>
<li>muscle twitching</li>
<li>overactive reflexes</li>
<li>poor coordination</li>
<li>shivering</li>
<li>sweating</li>
<li>trembling or shaking</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of netupitant / palonosetron may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Headache</li>
<li>fatigue</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>constipation</li>
<li>flushing or redness of the skin</li>
<li>heartburn</li>
<li>indigestion</li>
<li>stomach discomfort, upset, or pain</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to netupitant / palonosetron: oral capsule</i></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, dyspepsia</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal distention, abdominal pain, diarrhea, flatulence, nausea</p>
<p><b>Rare</b> (0.01% to 0.1%): Dysphagia, tongue coated</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Common</b> (1% to 10%): Constipation, dyspepsia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Dizziness, vertigo</p>
<p><b>Rare</b> (0.01% to 0.1%): Abnormal taste, hypoesthesia</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Erythema</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia, urticaria</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Common</b> (1% to 10%): Erythema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Insomnia</p>
<p><b>Rare</b> (0.01% to 0.1%): Acute psychosis, altered mood, sleep disorder</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Common</b> (1% to 10%): Asthenia, fatigue<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, fatigue</p>
<p><b>Rare</b> (0.01% to 0.1%): Feeling hot</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Uncommon</b> (0.1% to 1%): Fatigue<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Atrioventricular (AV) block, AV block first degree, bundle branch block, cardiomyopathy, conduction disorder, electrocardiogram QT prolonged, hypertension</p>
<p><b>Rare</b> (0.01% to 0.1%): Arrhythmia, AV block second degree, electrocardiogram ST segment depression, electrocardiogram ST-T segment abnormal, hypotension, increased troponin, mitral valve incompetence, myocardial ischemia, ventricular extrasystoles</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Postmarketing reports</b>: Shock<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Approximately 0.6% of patients given 0.5 mg of palonosetron developed AST greater than 3 times the upper limit of normal (ULN) and/or ALT greater than 3 x ULN with total bilirubin greater than ULN.  Approximately 0.2% of patients given the same dose of palonosetron developed AST greater than 10 x ULN and/or ALT greater than 10 x ULN with total bilirubin greater than ULN, and approximately 0.1% of patients developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN.</p>
<p></p>
<p>Approximately 0.3% of patients given oral formulations of netupitant-palonosetron developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than ULN, and AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN occurred in up to 0.1% of patients.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Elevated ALT, elevated AST, elevated total bilirubin, increased blood alkaline phosphatase</p>
<p><b>Rare</b> (0.01% to 0.1%): Increased blood bilirubin</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Uncommon</b> (0.1% to 1%): Elevated AST, elevated ALT, elevated total bilirubin<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Leukocytosis, neutropenia</p>
<p><b>Rare</b> (0.01% to 0.1%): Leukopenia, lymphocytosis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Increased blood creatine phosphokinase</p>
<p><b>Rare</b> (0.01% to 0.1%): Back pain, non-cardiac chest pain</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Uncommon</b> (0.1% to 1%): Myalgia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (0.01% to 0.1%): Blurred vision, conjunctivitis</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Uncommon</b> (0.1% to 1%): Eye swelling<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite</p>
<p><b>Rare</b> (0.01% to 0.1%): Hypokalemia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Increased blood creatinine</p>
<p><b>Rare</b> (0.01% to 0.1%): Cystitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Hiccups</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Frequency not reported</b>: Dyspnea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Palonosetron:</p>
<p><b>Postmarketing reports</b>: Anaphylactic/anaphylactoid reactions, anaphylaxis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between the oral and injectable formulations of Akynzeo?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Akynzeo (netupitant / palonosetron)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antiemetics</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Akynzeo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Nausea/Vomiting, Chemotherapy Induced</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to netupitant / palonosetron: oral capsule</i></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, dyspepsia</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal distention, abdominal pain, diarrhea, flatulence, nausea</p><p><b>Rare</b> (0.01% to 0.1%): Dysphagia, tongue coated</p><p></p><p>Palonosetron:</p><p><b>Common</b> (1% to 10%): Constipation, dyspepsia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p><b>Uncommon</b> (0.1% to 1%): Dizziness, vertigo</p><p><b>Rare</b> (0.01% to 0.1%): Abnormal taste, hypoesthesia</p><p></p><p>Palonosetron:</p><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Erythema</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia, urticaria</p><p></p><p>Palonosetron:</p><p><b>Common</b> (1% to 10%): Erythema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Insomnia</p><p><b>Rare</b> (0.01% to 0.1%): Acute psychosis, altered mood, sleep disorder</p><p></p><p>Palonosetron:</p><p><b>Common</b> (1% to 10%): Asthenia, fatigue<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, fatigue</p><p><b>Rare</b> (0.01% to 0.1%): Feeling hot</p><p></p><p>Palonosetron:</p><p><b>Uncommon</b> (0.1% to 1%): Fatigue<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Atrioventricular (AV) block, AV block first degree, bundle branch block, cardiomyopathy, conduction disorder, electrocardiogram QT prolonged, hypertension</p><p><b>Rare</b> (0.01% to 0.1%): Arrhythmia, AV block second degree, electrocardiogram ST segment depression, electrocardiogram ST-T segment abnormal, hypotension, increased troponin, mitral valve incompetence, myocardial ischemia, ventricular extrasystoles</p><p></p><p>Palonosetron:</p><p><b>Postmarketing reports</b>: Shock<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Approximately 0.6% of patients given 0.5 mg of palonosetron developed AST greater than 3 times the upper limit of normal (ULN) and/or ALT greater than 3 x ULN with total bilirubin greater than ULN.  Approximately 0.2% of patients given the same dose of palonosetron developed AST greater than 10 x ULN and/or ALT greater than 10 x ULN with total bilirubin greater than ULN, and approximately 0.1% of patients developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN.</p><p></p><p>Approximately 0.3% of patients given oral formulations of netupitant-palonosetron developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than ULN, and AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN occurred in up to 0.1% of patients.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Elevated ALT, elevated AST, elevated total bilirubin, increased blood alkaline phosphatase</p><p><b>Rare</b> (0.01% to 0.1%): Increased blood bilirubin</p><p></p><p>Palonosetron:</p><p><b>Uncommon</b> (0.1% to 1%): Elevated AST, elevated ALT, elevated total bilirubin<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Leukocytosis, neutropenia</p><p><b>Rare</b> (0.01% to 0.1%): Leukopenia, lymphocytosis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Increased blood creatine phosphokinase</p><p><b>Rare</b> (0.01% to 0.1%): Back pain, non-cardiac chest pain</p><p></p><p>Palonosetron:</p><p><b>Uncommon</b> (0.1% to 1%): Myalgia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (0.01% to 0.1%): Blurred vision, conjunctivitis</p><p></p><p>Palonosetron:</p><p><b>Uncommon</b> (0.1% to 1%): Eye swelling<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite</p><p><b>Rare</b> (0.01% to 0.1%): Hypokalemia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Increased blood creatinine</p><p><b>Rare</b> (0.01% to 0.1%): Cystitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Hiccups</p><p></p><p>Palonosetron:</p><p><b>Frequency not reported</b>: Dyspnea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Palonosetron:</p><p><b>Postmarketing reports</b>: Anaphylactic/anaphylactoid reactions, anaphylaxis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between the oral and injectable formulations of Akynzeo?</li>
</ul><h2>More about Akynzeo (netupitant / palonosetron)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antiemetics</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Akynzeo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Nausea/Vomiting, Chemotherapy Induced</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>